A Multicenter Open-Label Extension (OLE) Study To Assess The Long-Term Safety and Efficacy of Bempedoic Acid (ETC-1002) 180 MG

Trial Profile

A Multicenter Open-Label Extension (OLE) Study To Assess The Long-Term Safety and Efficacy of Bempedoic Acid (ETC-1002) 180 MG

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Bempedoic acid (Primary)
  • Indications Hypercholesterolaemia
  • Focus Adverse reactions
  • Acronyms CLEAR Harmony OLE
  • Sponsors Esperion Therapeutics
  • Most Recent Events

    • 20 Mar 2017 According to an Esperion Therapeutics media release, company plans to submit a new drug application (NDA) by 1H 2019 based on the successful completion of the global pivotal Phase 3 program. The US FDA also confirmed that LDL-C lowering program is adequate to support approval of an LDL-C lowering indication for bempedoic acid.
    • 03 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top